Board of Directors

Dr. Michael Tusche brings nearly 20 years of experience as a Scientist, Investor, Entrepreneur and Leader in the Biopharmaceutical sector. He currently serves as the CEO of 3io Therapeutics, Inc., a biotechnology company developing next generation viral immunotherapies. Prior to 3io, Michael was the CEO of Treadwell Therapeutics, a clinical stage company developing a multi-modality pipeline of first in class medicines for hard to treat solid and hematologic malignancies. Dr. Tusche was also the CSO and Co-Founder of Nirsum Laboratories, Inc., where he was Co-Inventor of the company’s foundational Intellectual Property, and a Principal Investigator of an NIH/NIDA grant awarded to the company. Prior to Nirsum, Michael was the Senior Analyst at Mountain Brook Capital Management, LLC, a Healthcare focused Long/Short equity only Hedge Fund, where his focus was Investments in publicly listed Biopharmaceutical companies. Before Mountain Brook, Dr. Tusche was an Associate at MLV and Co., a boutique investment bank with a focus on capital raising and advisory work for Life Science based companies. Dr. Tusche also led Biologic drug discovery at the Campbell Family Institute at the University Health Network in Toronto, Canada, where he managed a multidisciplinary R&D team in the pre-clinical development and validation of novel drug candidates for oncology, autoimmunity and inflammation. Michael started his career as a Scientist in drug discovery at Bayer AG in Japan, where he worked on early-stage development of small molecule GPCR antagonists for allergic and inflammatory diseases. Dr. Tusche received his B.Sc. (with Distinction) in Biochemisty from the University of Victoria. He also received a Ph.D. in Immunology and M.B.A. from the University of Toronto. He is co-author on several peer-reviewed publications, the recipient of numerous scientific and business awards, and named inventor on issued US patents focusing on small molecule and biologic therapeutics.